查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1591895

人类乳突病毒检测市场：按产品、最终用户、应用分类 - 2025-2030 年全球预测

Human Papillomavirus Testing Market by Product (Consumables, Systems), End-User (Clinical Diagnostic Laboratories, Hospitals, Physicians' Office Laboratories), Application - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 195 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023年，人类乳突病毒检测市值为11.1亿美元，预计到2024年将达到12.6亿美元，复合年增长率为13.58%，到2030年将达到27.1亿美元。

人类乳突病毒 (HPV) 检测是早期发现和预防子宫颈癌和其他 HPV 相关疾病的重要组成部分。在市场上，HPV 检测包括分子检测、基于 DNA 的检测和血清学检测，主要用于医院、诊断实验室和癌症研究中心等医疗机构。 HPV 感染盛行率的增加和子宫颈癌病例的相关增加推动了对 HPV 检测的需求，作为主要筛检方法和异常子宫颈抹片检查后的后续检测，因此强调了其重要应用。最终使用者包括医疗保健提供者、诊断中心和寻求早期准确诊断的患者。市场成长受到技术创新进步的显着影响，这些技术创新使 HPV 检测更加准确、价格实惠且易于使用。将人工智慧和机器学习整合到诊断工具中，有可能实现更复杂的分析和明智的决策。然而，某些人群的认知度低、保险范围有限以及高级诊断测试的高价格构成了巨大的限制和挑战。此外，各地区不同的监管标准进一步加剧了市场扩张的复杂性。为了抓住新的机会，相关人员将投资于旨在提高检测敏感性和特异性的研究，以及健康教育计画的策略，以提高人们对人类乳突病毒(HPV)疫苗接种和检测的认识和接受度。透过专注于开发可在资源匮乏的环境中部署的具有成本效益的模型，我们可以扩大我们的市场范围。市场情势本质上是竞争性的，迫使企业在应对监管环境的同时不断创新。创新成熟的领域包括开发将 HPV 检测与其他 STI 诊断相结合的综合检测平台，以及开发在提供便利且不影响可靠性的情况下提供便利的家庭检测解决方案。此外，利用公私伙伴关係合作可以加速市场的进步和采用。

主要市场统计
基准年[2023] 11.1亿美元
预测年份 [2024] 12.6亿美元
预测年份 [2030] 27.1亿美元
复合年增长率（%） 13.58%

市场动态：快速发展的人类乳突病毒检测市场的关键市场洞察

供需的动态交互作用正在改变人类乳突病毒检测市场。透过了解这些不断变化的市场动态，公司可以准备好做出明智的投资决策、完善策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，并了解消费行为及其对製造成本的影响，并更清楚地了解对采购趋势的影响。

  • 市场驱动因素
    • 子宫颈癌患者增加和人口老化
    • 提高对子宫颈癌筛检计画的认识
    • 政府措施和资金
  • 市场限制因素
    • 男性无法进行 HPV 检测
  • 市场机会
    • HPV初步筛检简介
    • HPV联合检测需求增加
  • 市场挑战
    • 赎回场景不明确

波特五力：驾驭人类乳突病毒检测市场的策略工具

波特的五力框架是理解市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解外部对人类乳突病毒检测市场的影响

外部宏观环境因素在塑造人类乳突病毒检测市场的绩效动态方面发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并为他们做出积极主动的决策做好准备。

市场占有率分析 了解人类乳突病毒检测市场的竞争状况

对人类乳突病毒测试市场的详细市场占有率分析可以对供应商的绩效进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV定位矩阵人类乳突病毒检测市场供应商的绩效评估

FPNV定位矩阵是评估人类乳突病毒检测市场供应商的重要工具。此矩阵允许业务组织根据供应商的商务策略和产品满意度评估供应商，从而做出符合其目标的明智决策。这四个象限使您能够清晰、准确地划分供应商，并确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析和建议描绘了人类乳突病毒检测市场的成功之路

对于旨在加强其在全球市场的影响力的公司来说，对人类乳突病毒检测市场的策略分析至关重要。透过审查关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机，并取得长期成功。

本报告对市场进行了全面分析，涵盖关键重点领域：

1. 市场渗透率：对当前市场环境的详细审查、主要企业的广泛资料、对其在市场中的影响力和整体影响力的评估。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5.产品开发与创新：重点关注可望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，以帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 子宫颈癌患者数量不断增加，人口老化加剧
      • 提高对子宫颈癌筛检计画的认识
      • 政府措施和资金
    • 抑制因素
      • 不提供男性 HPV 检测
    • 机会
      • HPV初步筛检简介
      • 对 HPV 同时检测的需求增加
    • 任务
      • 不确定的赎回场景
  • 市场区隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章人类乳突病毒检测市场：副产品

  • 消耗品
  • 系统

第七章 人类乳突病毒检测市场：依最终用户分类

  • 临床诊断实验室
  • 医院
  • 医生办公室检查室

第八章人类乳突病毒检测市场：依应用分类

  • 生物感测器
  • 染色体分析
  • 流式细胞技术
  • 免疫检测
  • 微阵列
  • 分子诊断
  • 单株和多株抗体

第九章美洲人类乳突病毒检测市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十章亚太人类乳突病毒检测市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十一章 欧洲、中东和非洲人乳头瘤病毒检测市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十二章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
  • 战略分析和建议

公司名单

  • Abbott Laboratories
  • Arbor Vita Corporation
  • Becton, Dickinson and Company
  • Cepheid
  • Dalrada Corporation
  • Everlywell Inc.
  • F. Hoffmann-La Roche AG
  • Fujirebio Diagnostics
  • IncellDx
  • Neodiagnostix
  • Nurx Inc.
  • OralDNA Labs
  • QIAGEN NV
  • Quest Diagnostics
  • Sansure Biotech Inc.
Product Code: MRR-43127F7278E2

The Human Papillomavirus Testing Market was valued at USD 1.11 billion in 2023, expected to reach USD 1.26 billion in 2024, and is projected to grow at a CAGR of 13.58%, to USD 2.71 billion by 2030.

Human Papillomavirus (HPV) testing is a vital component in the early detection and prevention of cervical cancer and other HPV-related conditions. Within the scope of the market, HPV testing encompasses molecular assays, DNA-based tests, and serological testing used primarily in healthcare settings such as hospitals, diagnostic laboratories, and cancer research centers. The necessity for HPV testing is driven by the increasing prevalence of HPV infections and the consequent rise in cervical cancer cases, emphasizing its critical application as both a primary screening method and a follow-up test post-abnormal Pap smear results. End-users broadly include healthcare providers, diagnostic centers, and patients looking for early and accurate diagnosis. Market growth is significantly influenced by advancing technological innovations which are making HPV tests more accurate, affordable, and accessible. Integration of artificial intelligence and machine learning in diagnostic tools holds promising potential for more sophisticated analysis and informed decision-making. However, the lack of awareness in certain demographics, limited insurance coverage, and high cost of advanced diagnostic tests pose substantial limitations and challenges. In addition, variations in regulatory standards across regions further complicate market expansion. To seize emerging opportunities, stakeholders should invest in research aimed at enhancing test sensitivity and specificity, and in strategies for health education programs to expand awareness and acceptance of HPV vaccination and testing. Focus on developing cost-efficient models that can be deployed in low-resource settings would broaden market reach. The market's nature is inherently competitive, with constant pressure to innovate while navigating regulatory landscapes. Areas ripe for innovation include developing integrated testing platforms that combine HPV detection with other STI diagnostics, and creating home-based testing solutions that provide convenience without compromising reliability. Leveraging partnerships across the private and public sectors could also accelerate market advancement and penetration.

KEY MARKET STATISTICS
Base Year [2023] USD 1.11 billion
Estimated Year [2024] USD 1.26 billion
Forecast Year [2030] USD 2.71 billion
CAGR (%) 13.58%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Human Papillomavirus Testing Market

The Human Papillomavirus Testing Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increasing number of cervical cancer cases and growing aging population
    • Growing awareness of cervical cancer screening programs
    • Government initiatives and funding
  • Market Restraints
    • Non-availability of HPV test for men
  • Market Opportunities
    • Introduction of HPV primary screening tests
    • Increasing Demand for HPV Co-testing
  • Market Challenges
    • Uncertain reimbursement scenario

Porter's Five Forces: A Strategic Tool for Navigating the Human Papillomavirus Testing Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Human Papillomavirus Testing Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Human Papillomavirus Testing Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Human Papillomavirus Testing Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Human Papillomavirus Testing Market

A detailed market share analysis in the Human Papillomavirus Testing Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Human Papillomavirus Testing Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Human Papillomavirus Testing Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Human Papillomavirus Testing Market

A strategic analysis of the Human Papillomavirus Testing Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Human Papillomavirus Testing Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Arbor Vita Corporation, Becton, Dickinson and Company, Cepheid, Dalrada Corporation, Everlywell Inc., F. Hoffmann-La Roche AG, Fujirebio Diagnostics, IncellDx, Neodiagnostix, Nurx Inc., OralDNA Labs, QIAGEN N.V., Quest Diagnostics, and Sansure Biotech Inc..

Market Segmentation & Coverage

This research report categorizes the Human Papillomavirus Testing Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Product, market is studied across Consumables and Systems.
  • Based on End-User, market is studied across Clinical Diagnostic Laboratories, Hospitals, and Physicians' Office Laboratories.
  • Based on Application, market is studied across Biosensors, Chromosome Analysis, Flow Cytometry, Immunoassays, Microarrays, Molecular Diagnostics, and Monoclonal & Polyclonal Antibodies.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing number of cervical cancer cases and growing aging population
      • 5.1.1.2. Growing awareness of cervical cancer screening programs
      • 5.1.1.3. Government initiatives and funding
    • 5.1.2. Restraints
      • 5.1.2.1. Non-availability of HPV test for men
    • 5.1.3. Opportunities
      • 5.1.3.1. Introduction of HPV primary screening tests
      • 5.1.3.2. Increasing Demand for HPV Co-testing
    • 5.1.4. Challenges
      • 5.1.4.1. Uncertain reimbursement scenario
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Human Papillomavirus Testing Market, by Product

  • 6.1. Introduction
  • 6.2. Consumables
  • 6.3. Systems

7. Human Papillomavirus Testing Market, by End-User

  • 7.1. Introduction
  • 7.2. Clinical Diagnostic Laboratories
  • 7.3. Hospitals
  • 7.4. Physicians' Office Laboratories

8. Human Papillomavirus Testing Market, by Application

  • 8.1. Introduction
  • 8.2. Biosensors
  • 8.3. Chromosome Analysis
  • 8.4. Flow Cytometry
  • 8.5. Immunoassays
  • 8.6. Microarrays
  • 8.7. Molecular Diagnostics
  • 8.8. Monoclonal & Polyclonal Antibodies

9. Americas Human Papillomavirus Testing Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Human Papillomavirus Testing Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Human Papillomavirus Testing Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Abbott Laboratories
  • 2. Arbor Vita Corporation
  • 3. Becton, Dickinson and Company
  • 4. Cepheid
  • 5. Dalrada Corporation
  • 6. Everlywell Inc.
  • 7. F. Hoffmann-La Roche AG
  • 8. Fujirebio Diagnostics
  • 9. IncellDx
  • 10. Neodiagnostix
  • 11. Nurx Inc.
  • 12. OralDNA Labs
  • 13. QIAGEN N.V.
  • 14. Quest Diagnostics
  • 15. Sansure Biotech Inc.

LIST OF FIGURES

  • FIGURE 1. HUMAN PAPILLOMAVIRUS TESTING MARKET RESEARCH PROCESS
  • FIGURE 2. HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY PRODUCT, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY PRODUCT, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 13. AMERICAS HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. UNITED STATES HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 15. UNITED STATES HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. ASIA-PACIFIC HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. HUMAN PAPILLOMAVIRUS TESTING MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 21. HUMAN PAPILLOMAVIRUS TESTING MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. HUMAN PAPILLOMAVIRUS TESTING MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. HUMAN PAPILLOMAVIRUS TESTING MARKET DYNAMICS
  • TABLE 7. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY CONSUMABLES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY SYSTEMS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY CLINICAL DIAGNOSTIC LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY PHYSICIANS' OFFICE LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY BIOSENSORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY CHROMOSOME ANALYSIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY FLOW CYTOMETRY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY IMMUNOASSAYS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY MICROARRAYS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY MONOCLONAL & POLYCLONAL ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. AMERICAS HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 23. AMERICAS HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 24. AMERICAS HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 25. AMERICAS HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 26. ARGENTINA HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 27. ARGENTINA HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 28. ARGENTINA HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 29. BRAZIL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 30. BRAZIL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 31. BRAZIL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 32. CANADA HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 33. CANADA HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 34. CANADA HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 35. MEXICO HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 36. MEXICO HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 37. MEXICO HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 38. UNITED STATES HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 39. UNITED STATES HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 40. UNITED STATES HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 41. UNITED STATES HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 42. ASIA-PACIFIC HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 43. ASIA-PACIFIC HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 44. ASIA-PACIFIC HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 45. ASIA-PACIFIC HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 46. AUSTRALIA HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 47. AUSTRALIA HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 48. AUSTRALIA HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 49. CHINA HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 50. CHINA HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 51. CHINA HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 52. INDIA HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 53. INDIA HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 54. INDIA HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 55. INDONESIA HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 56. INDONESIA HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 57. INDONESIA HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 58. JAPAN HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 59. JAPAN HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 60. JAPAN HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 61. MALAYSIA HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 62. MALAYSIA HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 63. MALAYSIA HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 64. PHILIPPINES HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 65. PHILIPPINES HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 66. PHILIPPINES HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 67. SINGAPORE HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 68. SINGAPORE HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 69. SINGAPORE HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 70. SOUTH KOREA HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 71. SOUTH KOREA HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 72. SOUTH KOREA HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 73. TAIWAN HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 74. TAIWAN HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 75. TAIWAN HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 76. THAILAND HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 77. THAILAND HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 78. THAILAND HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 79. VIETNAM HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 80. VIETNAM HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 81. VIETNAM HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 82. EUROPE, MIDDLE EAST & AFRICA HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 83. EUROPE, MIDDLE EAST & AFRICA HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 84. EUROPE, MIDDLE EAST & AFRICA HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 85. EUROPE, MIDDLE EAST & AFRICA HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 86. DENMARK HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 87. DENMARK HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 88. DENMARK HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 89. EGYPT HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 90. EGYPT HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 91. EGYPT HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 92. FINLAND HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 93. FINLAND HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 94. FINLAND HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 95. FRANCE HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 96. FRANCE HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 97. FRANCE HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 98. GERMANY HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 99. GERMANY HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 100. GERMANY HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 101. ISRAEL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 102. ISRAEL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 103. ISRAEL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 104. ITALY HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 105. ITALY HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 106. ITALY HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 107. NETHERLANDS HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 108. NETHERLANDS HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 109. NETHERLANDS HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 110. NIGERIA HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 111. NIGERIA HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 112. NIGERIA HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 113. NORWAY HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 114. NORWAY HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 115. NORWAY HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 116. POLAND HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 117. POLAND HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 118. POLAND HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 119. QATAR HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 120. QATAR HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 121. QATAR HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 122. RUSSIA HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 123. RUSSIA HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 124. RUSSIA HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 125. SAUDI ARABIA HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 126. SAUDI ARABIA HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 127. SAUDI ARABIA HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 128. SOUTH AFRICA HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 129. SOUTH AFRICA HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 130. SOUTH AFRICA HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 131. SPAIN HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 132. SPAIN HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 133. SPAIN HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 134. SWEDEN HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 135. SWEDEN HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 136. SWEDEN HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 137. SWITZERLAND HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 138. SWITZERLAND HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 139. SWITZERLAND HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 140. TURKEY HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 141. TURKEY HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 142. TURKEY HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 143. UNITED ARAB EMIRATES HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 144. UNITED ARAB EMIRATES HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 145. UNITED ARAB EMIRATES HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 146. UNITED KINGDOM HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 147. UNITED KINGDOM HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 148. UNITED KINGDOM HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 149. HUMAN PAPILLOMAVIRUS TESTING MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 150. HUMAN PAPILLOMAVIRUS TESTING MARKET, FPNV POSITIONING MATRIX, 2023